Heron Therapeutics, Inc. (FRA:AXD2)

Market Cap	206.48M
Revenue (ttm)	132.19M
Net Income (ttm)	-11.57M
Shares Out	n/a
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	4
Open	1.105
Previous Close	1.064
Day's Range	1.105 - 1.105
52-Week Range	0.901 - 2.370
Beta	n/a
RSI	65.38
Earnings Date	Feb 27, 2026

About Heron Therapeutics

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emeto...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1983
• Employees: 122
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: AXD2

Financial Performance

In 2024, Heron Therapeutics's revenue was $144.29 million, an increase of 13.57% compared to the previous year's $127.04 million. Losses were -$13.58 million, -87.72% less than in 2023.

Financial numbers in USD